There remains a severe shortfall of medical oncologists who are capable of a comprehensive study of clinically-relevant problems with human specimens in the laboratory, successful design and conduct clinical trials to improve prevention, detection, and treatment of human cancer, and very importantly, the translation of fundamental knowledge from the bench to the clinic. The shortage of medical oncologists over the next ten years continues. M. D. Anderson Cancer Center is well-suited to host a comprehensive training program that has the capability to reduce the severity of this shortfall.
The specific aims and overall objectives of this program remain unchanged: to train and nurture medical oncology fellows to ensure they are equipped to become the next leaders in every aspect of academic medical oncology. The training program herein provides three research training tracks for medical oncologists. The first track, the clinician investigator track provides training focused on development and implementation of clinical trials and associated correlative studies. The second track is the physician/scientist track which provides training for laboratory-based oncology research. And the third track is our community-based research track which takes advantage of our institution's extensive programs in cancer control and prevention. Fellows who complete this training program will be eligible for certification in the subspecialties of medical oncology and/or hematology. In addition, they will be able to provide the best hematology and medical oncology care available and also develop and lead independent research programs, conduct hypothesis-driven research, communicate their research findings through public presentations and publications in peer-reviewed journals, and obtain peer-reviewed grant support for their work.
This goal of this program is to provide training for the next generation of medical oncologists to perform cancer research, develop new approaches to treat and prevent cancer, and to treat cancer patients and survivors.
|Alrwas, Anas; Papadopoulos, Nicholas E; Cain, Suzanne et al. (2014) Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-? in patients with metastatic melanoma. Melanoma Res 24:342-8|
|Morrow, Phuong Khanh; Broxson, Anita C; Munsell, Mark F et al. (2014) Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer 14:e21-31|
|Rupaimoole, Rajesha; Wu, Sherry Y; Pradeep, Sunila et al. (2014) Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun 5:5202|
|Zhang, Jianjun; Fujimoto, Junya; Zhang, Jianhua et al. (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256-9|
|Akay, Catherine L; Ueno, Naoto T; Chisholm, Gary B et al. (2014) Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120:1319-28|
|Shetty, Aditya V; Matrana, Marc R; Atkinson, Bradley J et al. (2014) Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer 12:348-53|
|Pecot, Chad V; Rupaimoole, Rajesha; Yang, Da et al. (2013) Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4:2427|
|Matrana, M R; Duran, C; Shetty, A et al. (2013) Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49:3169-75|
|Dayyani, Farshid; Czerniak, Bogdan A; Sircar, Kanishka et al. (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189:1656-61|
|Lieu, C H; Lambert, L A; Wolff, R A et al. (2012) Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23:652-8|
Showing the most recent 10 out of 39 publications